S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
All the trading advice you’ve ever received boils down to this (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

InMed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INM)

$0.45
+0.01 (+2.27%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.41
$0.45
50-Day Range
$0.37
$0.99
52-Week Range
$0.29
$3.03
Volume
178,540 shs
Average Volume
263,972 shs
Market Capitalization
$2.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.00

InMed Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
9,900.0% Upside
$45.00 Price Target
Short Interest
Healthy
0.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of InMed Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars


INM stock logo

About InMed Pharmaceuticals Stock (NASDAQ:INM)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

INM Stock Price History

INM Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
InMed Pharmaceuticals Inc INM
Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
INM - InMed Pharmaceuticals Inc.
See More Headlines
Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
12/03/2023
Next Earnings (Estimated)
2/16/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INM
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.00
High Stock Price Target
$45.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+9,900.0%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-7,950,000.00
Net Margins
-147.87%
Pretax Margin
-147.74%

Debt

Sales & Book Value

Annual Sales
$4.14 million
Book Value
$1.82 per share

Miscellaneous

Free Float
5,182,000
Market Cap
$2.37 million
Optionable
Not Optionable
Beta
-0.04
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Eric A. Adams B.S. Chem. (Age 59)
    M.I.B., President, CEO & Director
    Comp: $347.82k
  • Mr. Michael Woudenberg P.Eng. (Age 54)
    Chief Operating Officer
    Comp: $287.54k
  • Ms. Alexandra Diane-Janet Mancini M.Sc. (Age 70)
    Senior Vice President of Clinical & Regulatory Affairs
    Comp: $279.39k
  • Dr. Sazzad Hossain M.Sc. (Age 65)
    Ph.D., Co-Founder
    Comp: $133.8k
  • Mr. Jonathan R. Tegge (Age 33)
    Interim Chief Financial Officer
  • Ms. Sarah Li CPA
    CGA, VP of Accounting & Controller
  • Colin Clancy
    Senior Director of Investor Relations
  • Mr. Jerry P. Griffin
    Vice President of Sales & Marketing
  • Dr. Eric Chih-Hsien Hsu (Age 53)
    Senior Vice President of Preclinical Research & Development
    Comp: $253.46k
  • Dr. Shane A. Johnson Ph.D.
    Senior VP & GM of BayMedica














INM Stock Analysis - Frequently Asked Questions

What is InMed Pharmaceuticals' stock price target for 2024?

0 Wall Street analysts have issued 12 month price targets for InMed Pharmaceuticals' stock. Their INM share price targets range from $45.00 to $45.00. On average, they expect the company's stock price to reach $45.00 in the next year. This suggests a possible upside of 9,900.0% from the stock's current price.
View analysts price targets for INM
or view top-rated stocks among Wall Street analysts.

How have INM shares performed in 2023?

InMed Pharmaceuticals' stock was trading at $2.02 on January 1st, 2023. Since then, INM stock has decreased by 77.7% and is now trading at $0.45.
View the best growth stocks for 2023 here
.

Are investors shorting InMed Pharmaceuticals?

InMed Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 4,900 shares, a decrease of 74.1% from the October 31st total of 18,900 shares. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is currently 0.0 days.
View InMed Pharmaceuticals' Short Interest
.

When is InMed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 16th 2024.
View our INM earnings forecast
.

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($6.25) EPS for the quarter, topping analysts' consensus estimates of ($8.75) by $2.50. InMed Pharmaceuticals had a negative trailing twelve-month return on equity of 57.65% and a negative net margin of 147.87%.

When did InMed Pharmaceuticals' stock split?

Shares of InMed Pharmaceuticals reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of InMed Pharmaceuticals?

Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INM) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -